Condition: Hereditary Transthyretin Amyloidosis With Polyneuropthy · Sponsor: Akcea Therapeutics
This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals · (844) 915-5145 · ionisNCT04850105study@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Study Centre | Sofia, Bulgaria | Recruiting |
| Study Centre | Égkomi, Nicosia, Cyprus | Recruiting |
| Study Center | Lille, Cedex, France | Recruiting |
| Study Center | Nice, Romaine, France | Recruiting |
| Study Centre | Nantes, France | Recruiting |
| Study Center | Heidelberg, Germany | Recruiting |
| Study Center | Athens, Greece | Recruiting |
| Study Center | Athens, Greece | Recruiting |
| Study Center | Heraklion, Greece | Recruiting |
| Study Centre | Roma, Rome, Italy | Recruiting |
| Study Center | Bologna, Italy | Recruiting |
| Study Center | Genova, Italy | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04850105